# RSV Vaccine Factsheet – Information for Patients, Parents and Carers

Source: https://www.keypedia.com/records/uk_mhra_guidance/uk-mhra/c2160c75-2ee5-44d6-a426-e6411861741f
Type: Guidance
Published: April 15, 2026
Updated: May 7, 2026

> This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines the clinical importance and safety profile of Respiratory Syncytial Virus (RSV) vaccines. RSV is a prevalent virus that typically results in mild cold-like symptoms but can escalate to severe conditions such as pneumonia and bronchiolitis in vulnerable populations, specifically infants and older adults. The MHRA confirms that all RSV vaccines approved for use in the UK have undergone rigorous assessment to ensure they meet high standards of safety, quality, and effectiveness. Under the UK regulatory framework, these vaccines are continuously monitored through the Yellow Card scheme, which allows for the ongoing surveillance of adverse reactions. The document details eligibility criteria, including the safety of administering RSV vaccines alongside COVID-19 shots and the importance of vaccination during pregnancy to protect newborns. Required actions for patients and caregivers include reviewing the provided safety information and reporting any suspected side effects via the Yellow Card scheme. As this is a public health factsheet rather than an enforcement letter, there are no specific company violations or inspection dates recorded. The primary objective is to facilitate informed decision-making for those at higher risk of serious illness.

---

## Content

Respiratory syncytial virus (RSV) is a common respiratory virus that can cause coughs, colds, and chest infections. While most people who catch RSV experience only mild illness, RSV can sometimes lead to serious illness, such as bronchiolitis and pneumonia, particularly in young babies, older adults, and individuals with weakened immune systems. RSV infection is one of the most common reasons for young babies to be admitted to hospital. In older adults, RSV can also lead to severe lung infections and breathing difficulties. Vaccination is one of the safest and most effective ways to protect people who are at higher risk of becoming seriously unwell with RSV. RSV vaccines used in the UK have been rigorously assessed for safety, quality and effectiveness, and are continuously monitored through the Yellow Card scheme. This factsheet is designed to help patients, parents and carers understand the RSV vaccines used in the UK. It covers: Overview of RSV RSV vaccination and eligibility Getting RSV and COVID-19 vaccination at the same time Safety and effectiveness of RSV vaccines RSV vaccine side effects RSV vaccine and pregnancy Who should not receive the RSV vaccine Report side effects to the Yellow Card scheme

## Attachments

- [RSV Vaccine Factsheet – Information for Patients, Parents and Carers](/government/publications/rsv-vaccine-factsheet-information-for-patients-parents-and-carers/rsv-vaccine-factsheet-information-for-patients-parents-and-carers)